Bio & Pharma
Lotte Biologics, Excellgene to collaborate on CDO biz
S.Korean pharma, Swiss-based bio company will jointly build cell line’s supply chain
By Apr 03, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Lotte Biologics, Excellgene to collaborate on CDO biz](https://www.kedglobal.com/data/ked/image/2023/04/03/ked202304030027.661x.0.jpg)
Lotte Biologics, South Korea's biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Sunday that it has entered into a memorandum of understanding (MOU) with Swiss-based cell line development company Excellgene for collaboration on contract development organization (CDO) services.
Excellgene provides cell line development services to global pharmaceutical companies and will join forces with Lotte Biologics to offer a comprehensive range of services, from cell line development to large-scale contract manufacturing of pharmaceutical cell lines.
Under the agreement, Excellgene will be responsible for cell line and high-yield process development, while Lotte Biologics will provide cell bank services and manufacture clinical and commercial pharmaceuticals.
"Enhancing CDO capabilities requires significant time and specialized personnel, but it is crucial for us to become a global CDMO company," said Lee Dong-wook, CEO of Lotte Biologics. "Through our partnership with Excellgene, which has vast experience working with leading global firms, we aim to boost not just our CMO, but also our CDO competitiveness."
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
Bio & PharmaSamsung Biologics to invest $762 mn for 5th CDMO factory
Mar 16, 2023 (Gmt+09:00)
2 Min read -
-
Bio & PharmaMedipost acquires Canada’s OmniaBio for CDMO business
May 31, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaK-bio firms embrace gene therapy CDMO as Samsung looks the other way
Aug 05, 2022 (Gmt+09:00)
3 Min read
Comment 0
LOG IN